trial

An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia

NCTId NCT01646827
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 37 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2013-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
37 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2012-05
Primary completion
2013-04
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Investigators

1
Timothy Peters-Strickland, MDStudy Director

Sites

6 total
Cerritos, United StatesGarden Grove, United StatesSan Diego, United StatesSanta Ana, United StatesWashington D.C., United StatesAustin, United States

Facts & assertions

4 sourced
Enrollment
37
Phase
PHASE1
Primary Completion Date
2013-04
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Timothy Peters-Strickland, MD
person